RT Journal Article
SR Electronic
T1 Genetic Contributions to Early and Late Onset Ischemic Stroke
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.06.21265795
DO 10.1101/2021.11.06.21265795
A1 Jaworek, Thomas
A1 Xu, Huichun
A1 Gaynor, Brady J.
A1 Cole, John W.
A1 Rannikmäe, Kristiina
A1 Stanne, Tara M.
A1 Tomppo, Liisa
A1 Abedi, Vida
A1 Amouyel, Philippe
A1 Armstrong, Nicole. D
A1 Attia, John
A1 Bell, Steven
A1 Benavente, Oscar R.
A1 Boncoraglio, Giorgio B.
A1 Butterworth, Adam
A1 ,
A1 Cárcel-Márquez, Jara
A1 Chen, Zhengming
A1 Chong, Michael
A1 Cruchaga, Carlos
A1 Cushman, Mary
A1 Danesh, John
A1 Debette, Stephanie
A1 Duggan, David J.
A1 Durda, Jon Peter
A1 Engstrom, Gunnar
A1 Enzinger, Christian
A1 Faul, Jessica D.
A1 Fecteau, Natalie S.
A1 Fernández-Cadenas, Israel
A1 Geiger, Christian
A1 Giese, Anne-Katrin
A1 Grewal, Raji P.
A1 Grittner, Ulrike
A1 Havulinna, Aki S.
A1 Heitsch, Laura
A1 Hochberg, Marc C.
A1 Holliday, Elizabeth
A1 Hu, Jie
A1 Ilinca, Andreea
A1 ,
A1 ,
A1 Irvin, Marguerite R.
A1 Jackson, Rebecca D.
A1 Jacob, Mina A.
A1 Janssen, Raquel Rabionet
A1 Jimenez-Conde, Jordi
A1 Johnson, Julie A.
A1 Kamatani, Yoichiro
A1 Kardia, Sharon L.R.
A1 Koido, Masaru
A1 Kubo, Michiaki
A1 Lange, Leslie
A1 Lee, Jin-Moo
A1 Lemmens, Robin
A1 Levi, Christopher
A1 Li, Jiang
A1 Li, Liming
A1 Lin, Kuang
A1 Lopez, Haley
A1 Luke, Sothear
A1 Maguire, Jane
A1 McArdle, Patrick F.
A1 McDonough, Caitrin W.
A1 Meschia, James F.
A1 Metso, Tiina
A1 Müller-Nurasyid, Martina
A1 O’Connor, Timothy
A1 O’Donnell, Martin
A1 Peddareddygari, Leema Reddy
A1 Pera, Joanna
A1 Perry, James A.
A1 Peters, Annette
A1 Putaala, Jukka
A1 Ray, Debashree
A1 Rexrode, Kathryn
A1 Ribases, Marta
A1 Rosand, Jonathan
A1 Rothwell, Peter M.
A1 Rundek, Tatjana
A1 Ryan, Kathleen A.
A1 Sacco, Ralph L.
A1 Salomaa, Veikko
A1 Sanchez-Mora, Cristina
A1 Schmidt, Reinhold
A1 Sharma, Pankaj
A1 Slowik, Agnieszka
A1 Smith, Jennifer A.
A1 Smith, Nicholas L.
A1 Wassertheil-Smoller, Sylvia
A1 Soderholm, Martin
A1 Stine, O. Colin
A1 Strbian, Daniel
A1 Sudlow, Cathie LM
A1 Tatlisumak, Turgut
A1 Terao, Chikashi
A1 Thijs, Vincent
A1 Torres-Aguila, Nuria P.
A1 Trégouët, David-Alexandre
A1 Tuladhar, Anil Man
A1 Veldink, Jan H.
A1 Walters, Robin G.
A1 Weir, David R.
A1 Woo, Daniel
A1 Worrall, Bradford B.
A1 Hong, Charles C
A1 Ross, Owen
A1 Zand, Ramin
A1 de Leeuw, F-E
A1 Lindgren, Arne G.
A1 Pare, Guillaume
A1 Anderson, Christopher D.
A1 Markus, Hugh S.
A1 Jern, Christina
A1 Malik, Rainer
A1 Dichgans, Martin
A1 Mitchell, Braxton D.
A1 Kittner, Steven J.
A1 ,
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/11/08/2021.11.06.21265795.abstract
AB Objective To determine the contribution of common genetic variants to risk of early onset ischemic stroke (IS).Methods We performed a meta-analysis of genome-wide association studies of early onset IS, ages 18-59, using individual level data or summary statistics in 16,927 cases and 576,353 non-stroke controls from 48 different studies across North America, Europe, and Asia. We further compared effect sizes at our most genome-wide significant loci between early and late onset IS and compared polygenic risk scores for venous thromboembolism between early versus later onset IS.Results We observed an association between early onset IS and ABO, a known stroke locus. The effect size of the peak ABO SNP, rs8176685, was significantly larger in early compared to late onset IS (OR 1.17 (95% C.I.: 1.11-1.22) vs 1.05 (0.99-1.12); p for interaction = 0.008). Analysis of genetically determined ABO blood groups revealed that early onset IS cases were more likely to have blood group A and less likely to have blood group O compared to both non-stroke controls and to late onset IS cases. Using polygenic risk scores, we observed that greater genetic risk for venous thromboembolism, another prothrombotic condition, was more strongly associated with early, compared to late, onset IS (p=0.008).Conclusion The ABO locus, genetically predicted blood group A, and higher genetic propensity for venous thrombosis are more strongly associated with early onset IS, compared with late onset IS, supporting a stronger role of prothrombotic factors in early onset IS.Competing Interest StatementA. Butterworth reports grants outside of this work from AstraZeneca, Biogen, BioMarin, Bioverativ, Merck, Novartis, Pfizer and Sanofi and personal fees from Novartis. J. Carcel-Marquez is supported by an AGAUR Contract (agencia de gestio d'ajuts universitaris i de recerca; FI_DGR 2019, grant number 2019_FI_B 00853) co-financed with Fons Social Europeu (FSE). . J. Danesh reports grants, personal fees and non-financial support from Merck Sharp & Dohme (MSD), grants, personal fees and non-financial support from Novartis, grants from Pfizer and grants from AstraZeneca outside the submitted work. J. Danesh sits on the International Cardiovascular and Metabolic Advisory Board for Novartis (since 2010); the Steering Committee of UK Biobank (since 2011); the MRC International Advisory Group (ING) member, London (since 2013); the MRC High Throughput Science Omics Panel Member, London (since 2013); the Scientific Advisory Committee for Sanofi (since 2013); the International Cardiovascular and Metabolism Research and Development Portfolio Committee for Novartis; and the Astra Zeneca Genomics Advisory Board (2018). A.M. Tuladhar is a junior staff member of the Dutch Heart Foundation (grant number 2016T044). F.E. de Leeuw received a grant from the Dutch Heart Foundation (grant 2014 T060 to FE.d.L) and Bike4Brains. AMT received a grant from the Dutch Heart Foundation (grant 2016 T044 to A.M.T) and from the Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation (CVON 2018-28 & 2012-06 Heart Brain Connection to A.M.T). A.G. Lindgren reports personal fees from Bayer, Astra Zeneca, BMS Pfizer, and Portola. G.Pare reports no disclosures relevant to the manuscript. C.D. Anderson receives sponsored research support from the National Institutes of Health of the United States (R01NS103924, U01NS069763), the American Heart Association, the Bugher Foundation, Massachusetts General Hospital, and Bayer AG, and has consulted for ApoPharma and Invitae Funding StatementStudy Funding: This study was supported by the National Institutes of Health grants R01 NS105150, R01 NS100178 and R01NS114045 and Department of Veterans Affairs grant BX004672-01A1. The project utilized the resources and facilities at the VA Maryland Health Care System, Baltimore, Maryland. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. Tom Jaworek was supported by a T32 AG000262 Epidemiology of Aging grant. Huichun Xu was supported by AHA Career Development Award (19CDA34760258). Please see Supplemental Materials for the funding and acknowledgements for each contributing studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Maryland Human Subjects Protection Office gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary results will be made available upon application to the contact authors and consortium approval of the request. Individual level data from a subset of sites will be made available on dbGaP.